Mimetogen Pharmaceuticals Inc.
This article was originally published in Start Up
Executive SummaryMimetogen Pharmaceuticals Inc.'s founding goal was to use synthetic analogs of nerve growth factor to protect the retinal ganglion cells of the optic nerve that die as glaucoma progresses. In doing so, it intended to show that its drugs provided neuroprotective ability and also enhanced this effect for other treatments prescribed to lower intraocular pressure. Mimetogen validated that program in animals, but given the cost and length of clinical trials for glaucoma, the company switched gears and began developing its NGF mimetics as potential treatments for dry eye.
You may also be interested in...
As Roche’s reported interest in buying rare-disease specialist Alexion faded, new suitors popped up for oncology specialist Onyx. Plus news on deals between Spectrum and Talon, Pfizer and Sequella, Medtronic and Amgen, and a new direction for Rexahn.